Saba Abdul Hameed

Sindh Institute of Urology & Transplantation (SIUT), Karachi, Pakistan

Abstract Title: Role of Radiopharmaceuticals for Cancer Imaging and Therapy

Biography: I, Saba Abdul Hameed completed my BS in Nuclear Medicine and Radiotherapy from Sindh Institute of Medical Sciences (SIMS), Karachi. Deployed as a Nuclear Medicine technologist position in Sindh Institute of Urology & Transplantation (SIUT) since 5 years.

Research Interest: Radiopharmaceutical also known as radioactive drugs use for diagnosis and treatment of various types of cancers in healthcare systems. Pharmaceuticals labeled with radioisotopes by two methods i.e.; direct labeling and indirect labeling (requiring a reducing agent for labeling). Radioisotopes created by bombarding stable molecules with particles in nuclear reactor to produce unstable radioactive nuclei. Produce by three methods including nuclear reactor, generator and cyclotron (produce proton rich isotopes like Fl18). Various radiopharmaceuticals used for tumor imaging and treatment, for diagnosis includes Tc99m Methylene Diphosphonate (MDP) for Bone cancer and Metastasis, Tc99m Methoxy Isobutile Isonitrile (MIBI) for Parathyroid tumors, I123Meta Iodobenzyl Guanidine (MIBG) for Neuroendocrine Tumors, Ga68 DOTATOC for Neuroendocrine tumors and Ga68 Prostate Specific Membrane Antigen (PSMA) for Prostate Carcinoma. Therapeutic radiopharmaceuticals include MIBG I131 for Neuroblastoma, Phosphorus32 for Bone cancer and Yitrium90 for Hepatocellular Carcinome. Future of radiopharmaceuticals is very promising in cancer imaging and therapy through AI driven insights confirming precise treatment of complex tumors, playing major role in market by increasing investments for pharmaceuticals companies, important foundational aspect of healthcare.